Cure 360: MECP2 Reactivation | Interview with Kyle Fink, PhD | Rett Syndrome Research Trust

Kyle Fink, PhD, is one of several scientists collaborating on an MECP2 reactivation approach to cure Rett syndrome, which aims to awaken the healthy and silenced MECP2 gene in every girl with Rett. In collaboration with the labs of Toni Bedalov, MD, PhD, and Shawn Liu, PhD, Dr. Fink is using epigenome editing to achieve reactivation. Learn more in this short interview about the recent advances in knowledge and technology that are driving his research forward.

---------------------------------
The Rett Syndrome Research Trust is singularly focused on a cure for Rett syndrome and related MECP2 disorders. Achieving success takes a deep understanding of the relevant science, an environment built for scientific collaboration, and experience with drug and business development. Today we are building on incredible scientific and industry momentum by implementing six genetic-based strategies that tackle Rett from every angle. Every single company pursuing a cure for Rett is able to do so because they leveraged discoveries and resources that were generated with RSRT funding. RSRT is the home of the Rett cure community, and we are confident that together we will cure Rett syndrome.